Immix Biopharma (IMMX) announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18 clinical trial sites in its national footprint. “We are thrilled to report that NEXICART-2 is progressing faster than we expected. Responding to the unmet need across the country, we are expanding the NEXICART-2 clinical trial footprint to deliver cell therapy to this underserved population, where no FDA drugs are approved today,” said Ilya Rachman, CEO.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma Holds Annual Meeting, Elects Directors
- Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
- Immix Biopharma files $13.45M common stock ATM offering
- Immix Biopharma Enters At The Market Offering Agreement
- Immix Biopharma announces NXC-201 trial met primary endpoint